News Releases News Releases HOME HOME



March 18, 2004

Launch of Three External Analgesics under "Menfula" Brand Name
Potent Against Shoulder, Back, Joint and Muscular Pain





Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) will release on March 22 three external analgesics comprising "Menfula Lotion", "Menfula Cool Ointment" and "Menfula Gel", contain piroxicam, a pain and inflammation reducer used in medical application. 

The active ingredient piroxicam is highly effective at soothing pain and inflammation by inhibiting production of the pain producing and enhancing substance prostaglandin. "Menfula Lotion" comes in a side-spreading container ideal for applying lotion on such hard-to-reach places as the shoulders and back. "Menfula Cool Ointment" is a refreshingly cool ointment that spreads easily over a wide area, and is best suited to treating muscular pain in the arm and foot. "Menfula Gel", with a nice icy feel, is most effective for treating inflammation, such as bruises and sprains, as well as joint pain in the hands and feet. "Menfula Gel" is free of annoying odors such as menthol. 

The three products scheduled for release are the successors to the "Pirocut" brand of pain-reducing poultices contain piroxicam, for which sales rights were acquired from Toyama Chemical Co., Ltd. in February 2003. Taisho Pharmaceutical aims to increase sales further by strengthening sales promotion activities at stores through direct sales of the new products added to the Company's product lineup under the "Menfula" brand.

Product specification

Product name Menfula Lotion Menfula Cool Ointment Menfula Gel
Packaging 50g 50g 50g
Suggested retail price ¥1,400
(excl. tax)
¥1,400 
(excl. tax)
¥1,400 
(excl. tax)
Ingredient (per 1g)

Piroxicam: 5.0mg

Indications Pain in the shoulders (including stiff shoulders), lower back, joints, muscles, tenosynovitis (pain in the hands or wrists), elbows (including tennis elbow), contusion, and sprains.
Dosage Spread over affected area 3-4 times per day. Spread over affected area 3-4 times per day. Spread over affected area 3-4 times per day.
Date of sale March 22, 2004
Expected sales ¥1.0 billion (one year from date of sale)